The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.
Guillermo Garcia-Manero
No relevant relationships to disclose
Giovanni Martinelli
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche
Honoraria - Bristol-Myers Squibb; Novartis
Joshua F. Zeidner
No relevant relationships to disclose
David Avigan
No relevant relationships to disclose
Kenneth Carl Anderson
No relevant relationships to disclose
Vincent Ribrag
No relevant relationships to disclose
Craig Moskowitz
No relevant relationships to disclose
Pier Luigi Zinzani
No relevant relationships to disclose
Dianna Wu
Employment or Leadership Position - Merck
Kenneth Emancipator
Employment or Leadership Position - Merck
Marisa Dolled-Filhart
Employment or Leadership Position - Merck
Christine Gause
Employment or Leadership Position - Merck
Holly Brown
Employment or Leadership Position - Merck
Ryan D. Geschwindt
Employment or Leadership Position - Merck
Robert Iannone
Employment or Leadership Position - Merck
Stock Ownership - Merck
Shelonitda Rose
Employment or Leadership Position - Merck
Phillippe Armand
Consultant or Advisory Role - Merck